Evidence map›Paper›PMID 33128488›Full record

ArticleThe Kaohsiung journal of medical sciences2021

Skimmin protects diabetic cardiomyopathy in streptozotocin-induced diabetic rats.

Rui-Kai Liang, Yun-Yun Zhao, Mei-Li Shi, Gang Zhang, Yong-Jun Zhao, Bing-Gui Zhang, Rui-Jing Liang

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The Role of HInternational journal of molecular sciences · 2022
    Review
  9. Targeting Pyroptosis: New Insights into the Treatment of Diabetic Microvascular Complications.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rui-Kai LiangDepartment of Endocrinology, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Yun-Yun ZhaoDepartment of Cardiovascular Medicine, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Mei-Li ShiDepartment of Cardiovascular Medicine, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Gang ZhangDepartment of Cardiovascular Medicine, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Yong-Jun ZhaoDepartment of Cardiovascular Medicine, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Bing-Gui ZhangDepartment of General Surgery, Hebei Geriatric Hospital, Shijiazhuang, Hebei, China.
Rui-Jing LiangDepartment of Geriatrics, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Hebei General Hospital · CNFirst Affiliated Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skimmin, a natural coumarin derivate, has been showed to be protective against experimental diabetic nephropathy; however, its protective effect on diabetic cardiomyopathy (DCM) is not clarified. By using in vitro and in vivo models, we investigated skimmin's protective effect on impaired heart tissues in DCM. DCM was induced by streptozotocin (STZ, 60 mg/kg) using Sprague Dawley rats, and diabetic rats were treated with either skimmin (15 or 30 mg/kg) or the vehicle for 16 weeks, and normal rats were used as a control. Hematoxylin and eosin and Masson's trichrome staining were performed to evaluate the cardiac histopathology, and the oxidative stress and proinflammation cytokines in heart tissues were measured. The protein levels of key mediators in fibrosis, pyroptosis, and autophagy in heart tissues were investigated using western blotting. In vitro, primary neonatal cardiomyocytes were treated with skimmin (2 and 10 μM) under stimulation by high glucose (30 mM) and low glucose (5 mM) respectively, and the molecular mechanisms on pyroptosis and autophagy were studied. Compared to the vehicle-treated DCM group, skimmin treatment significantly improved the ejection fraction and fractional shortening of the left ventricle and reduced the oxidative stress by increasing the glutathione level and activity of superoxide dismutase and catalase. Skimmin also reduced cardiac fibrosis, and decreased proinflammation cytokines in cardiac tissues. Mechanism studies showed skimmin may enhance the autophagy and ameliorate NLRP3 inflammasome activation to play a protective role in DCM. This study, for the first time, indicates that skimmin might be a promising lead compound for DCM.

Indexed as

AnimalsAutophagyBody WeightCardiotonic AgentsCaspase 1Chronic DiseaseCoumarinsCytokinesDiabetes Mellitus, ExperimentalDiabetic CardiomyopathiesGlucoseHeartHeart RateInflammationInflammation MediatorsInterleukin-1betaCardiotonic AgentsCaspase 1CoumarinsCytokinesGlucoseInflammation MediatorsInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinskimminStreptozocinautophagydiabetic cardiomyopathyinflammationoxidative stressskimmin

Identifiers

PMID33128488
PMCPMC11896253
OpenAlexW3095630081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.